Milestone Pharmaceuticals Inc. Total Long-Term Debt
Milestone Pharmaceuticals Inc. (MIST) had Total Long-Term Debt of $59.21 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-08-12
- 2026-06-30: Long-term Debt $59.21M.
- 2026-03-31: Long-term Debt $58.19M.
- 2025-12-31: Long-term Debt $57.19M.
- 2025-09-30: Long-term Debt $56.21M.
| Period end | Long-term Debt |
|---|---|
| 2026-06-30 | $59.21M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $58.19M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $57.19M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $56.21M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $55.24M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $54.29M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $53.35M 10-K · filed 2026-03-20 |
| 2024-09-30 | $52.43M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $51.53M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $50.64M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $49.77M 10-K · filed 2025-03-13 |
| 2023-09-30 | $48.91M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $48.07M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $47.32M 10-Q · filed 2023-05-11 |
| 2019-12-31 | $0.00 10-K/A · filed 2020-10-23 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-13 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-13 |
| 2019-03-31 | $0.00 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |